|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 27, 20942-20948, July 7, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, March 27, 2000
Regulation of mammalian cell growth and
proliferation is governed through receptor-mediated signaling networks
that ultimately converge on the cell cycle machinery. Adaptor proteins
play essential roles in the formation of intracellular signaling
complexes, relaying extracellular signals from the plasma membrane to
the nucleus of a cell. The leukocyte-specific adaptor protein Grap2 is
a central linker protein in immune cell signaling and activation. Using Grap2 as bait protein, we identified a novel human protein, GCIP (Grap2 cyclin-D interacting
protein). We found that GCIP bound to Grap2 in both yeast
two-hybrid assays and in mammalian cells through binding to the
COOH-terminal unique domain and SH3 domain (designated QC domain) of
Grap2. GCIP also associated with cyclin D both in vitro and
in vivo. The expression of GCIP was found in all human
tissues examined with the highest level of expression in the heart,
muscle, peripheral blood leukocytes, and brain. Furthermore,
phosphorylation of retinoblastoma protein by cyclin D-dependent protein kinase was reduced and E2F1-mediated
transcription activity was inhibited in cells transfected with GCIP.
High level expression of GCIP in terminally differentiated tissues and
the inhibition of E2F1 transcription activation suggest that GCIP could
play an important role in controlling cell differentiation and proliferation.
In response to extracellular mitogenic and growth signals, cells
initiate different signaling pathways that ultimately lead to the
transcriptional activation of downstream genes and cell proliferation.
One set of the genes that respond to mitogenic signals encodes the
D-type cyclins (D1, D2, and D3). These cyclins assemble with their
catalytic partners, CDK4 and CDK6, as cells progress through the first
gap phase (G1) to the initiation of DNA synthesis (S phase)
(1). Assembled cyclin D-Cdk complexes then enter the cell nucleus where
they are phosphorylated and activated by CDK-activated kinases. The
active cyclin D-Cdk complexes participate in the phosphorylation of the
retinoblastoma retinoblastoma protein
(Rb),1 resulting in the
functional inactivation of Rb and the progression of the cell through
the late G1 restriction point into the S phase (2, 3). Rb
exerts its growth regulatory functions at least in part by inhibiting
the transcriptional activity of E2F, a family of transcription factors
that play a major role in cell proliferation, differentiation,
apoptosis, and cell cycle progression (4, 5, 7). It has been known that
E2F proteins mediate the transactivation of a set of genes that
controls cellular progression through G1 into the S phase.
By binding to the activation domain of E2F, Rb protein actively
represses transcription from promoters containing E2F-binding sites,
resulting in the arrest of cell cycle progression (3, 6-8). Therefore,
disruption of the Rb gene by deletion, mutation, or inactivation by
phosphorylation or viral oncoproteins causes the release of free,
transcriptional active E2F family of proteins, leading to the
unrestricted cell proliferation (4, 5, 8). Understanding the regulation
of cyclin D-dependent protein kinases, their
phosphorylation of Rb, and their activation of E2F-mediated
transcriptional activation will provide insight into the molecular
mechanism of cell differentiation and proliferation.
Recently, adaptor proteins or scaffold proteins have been shown to play
important roles in the regulation of signaling networks and in
determining the specificity and selectivity of signaling pathways (9,
10). Examples include the mitogen-activated protein kinase complexes
coordinated by the scaffold proteins Ste5p and Pbs2p in yeast
Saccharomyces cerevisiae (11), the c-Jun
NH2-terminal kinase signaling complexes by JIP-1 (12), and
the signaling complexes mediated by T-cell-specific LAT proteins (13).
Recently, we identified a novel leukocyte-specific adaptor protein,
Grap2, in immune tissues (14). Like Grb2, Grap2 contains two SH3
domains and one SH2 domain in its structure. However, Grap2 has a 120- amino acid glutamine-/proline-rich domain between the SH2 domain and
the COOH-terminal SH3 domain. The expression of Grap2 is highly tissue-
and cell-specific, found only in immune tissues and in T lymphocytes
and monocytes/macrophages. Although the roles of Grap2 in immune cell
signaling and activation is not clear at this moment, it can form
signaling complexes with a number of signaling molecules in T cells and
leukemia cells to relay extracellular signals from the plasma membrane
to the nucleus of the cells.
In this report, we describe the cloning of a novel human protein, GCIP,
that interacts with Grap2 and cyclin D. In yeast two-hybrid assays and
in mammalian cells, GCIP interacts with full-length Grap2 protein and
with the COOH-terminal unique and SH3 domains (designated QC domain) of
Grap2. Unlike the highly restricted expression of Grap2, GCIP is
ubiquitously expressed in all human tissues examined with a high level
of expression in the heart, muscle, peripheral blood leukocytes,
kidney, and brain, where cell differentiation and proliferation is
limited. Furthermore, we found that GCIP associates with cyclin D1 both
in vitro and in mammalian cells. In the presence of GCIP,
phosphorylation of the retinoblastoma (Rb) protein by cyclin
D-dependent Cdk4 kinase was partially inhibited.
Overexpression of GCIP in mammalian cells suppressed the E2F1-mediated
transcriptional activity, which is required for the transition of the
G1 phase to the S phase in cell cycle progression. Together
these data suggest that GCIP is a novel human protein potentially
involved in the regulation of cell differentiation and proliferation
through Grap2 and cyclin D-mediated signaling pathways.
Plasmid Construction for the Yeast Two-hybrid System--
The
unique proline/glutamine-rich domain and the COOH-terminal SH3 domain
(QC domain) of Grap2 cDNA (14) was subcloned into yeast plasmid
pAS2-1 (CLONTECH, Palo Alto, CA) to create an
in-frame fusion with the GAL4 DNA-binding domain gene. The pAS2-Grap2QC was transformed into yeast strain PJ69-2A using the lithium acetate procedure and plated onto synthetic complete (SC) media lacking tryptophan and adenine. Pretransformed human bone marrow cDNA library (CLONTECH) was mated with the bait strain
for 20 h, and then plated on SC medium plates without tryptophan,
leucine, adenine, and histidine. The transformed yeast cells were grown
at 30 °C for 3-7 days. Transformants grown on the quadruple dropout
plates were assayed for GCIP and Grap2 Plasmid Constructs--
Full-length GCIP was
cloned into mammalian expression vectors pCMV-HA
(CLONTECH) or pCMV-Tag1 (Promega, WI) by PCR using
two oligonucleotide primers. The oligonucleotides used were the
following: 5'-GAAGATCTAGATGGCGAGCGCAACTGCA-3' and
5'-GGGGTACCTCATAATTCAAGTTCACTCTGAG-3'. PCR products were digested
with BglII and KpnI, and cloned into pCMV-HA
vector with an in-frame hemagglutinin (HA)-epitope sequence or
Flag-epitope sequence at the 5' end. For construction of glutathione S-transferase (GST)-GCIP protein, full-length GCIP or the
COOH-terminal domain of GCIP were subcloned into pGEX4T-1 (Amersham
Pharmacia Biotech) vector by PCR. GST fusion proteins corresponding to
the full-length of Grap2, the SH2 domain, and the QC domain of Grap2 were constructed by PCR and subcloned into pGEX-2TK. Sequences of the
expression constructs were confirmed by automatic DNA sequencing.
Northern Blot Analysis and RT-PCR--
Multi-tissue
poly(A+) blots with 2 µg/lane RNA from 16 different human
tissues were obtained from CLONTECH. The probe used was a full-length GCIP cDNA of ~1.2 kilobases obtained by
restriction digestion of the GCIP plasmid. The cDNA probe was
radiolabeled with [
cDNAs from different immune tissues were obtained from
CLONTECH. Specific primers
(5'-CTACAACAGTGTCTGGGTTGCGTGCC, 3'-GTATCAGAGCCTGTCCATGTCGATGAG) corresponding to the COOH-terminal region of GCIP were used in the
RT-PCR reaction. Primers for glyceraldehyde-3-phosphate dehydrogenase were used as a positive control and the standard for the amount of
cDNA used in the PCR.
Cell Lines and Cell Transfection--
Different cells were
cultured as described in appropriate culture medium. COS-7 and 293T
cells (1 × 105 cells/well) were transfected with
plasmids as indicated by LipofectAMINE according to the manufacturer's
recommendation (Life Technologies, Bethesda, MD). Jurkat T cells and
K562 cells were transfected by electroporation at settings of 960 microfarads and 250 volts. 12-16 h after transfection, the medium was
replaced with fresh medium. 36-48 h after transfection, the cells were
harvested and lysed in lysis buffer (150 mM NaCl, 20 mM HEPES, pH 7.4, 2 mM EGTA, 50 mM
Expression vectors, pCGE2F1, pCMVE2F1VP16, and the pG5E1BCAT are kind
gifts from Dr. David Johnson (University of Texas, M.D. Anderson Cancer
Center) (16). For GAL4 and VP16 fusions, a total of 2 µg of plasmids
was used in transfections for CAT reporter assays and 10 µg of
plasmids was used in luciferase transfection assays. pCMV-LacZ vector
was used as an internal control for normalization in all transfections.
In Vitro Binding Assays, Coimmunoprecipitations, and Western
Blots--
GST-Grap2 and GST-GCIP fusion proteins were purified as
recommended by the manufacturer (Amersham Pharmacia Biotech) and used in an in vitro protein binding assay. Briefly,
COS-7-transfected cell lysate was incubated with comparable amounts of
resin-bound GST fusion proteins. The beads were washed three times in
the lysis buffer (150 mM NaCl, 20 mM HEPES, pH
7.4, 2 mM EGTA, 50 mM glycerophosphate, 1%
Triton X-100, 0.5% Nonidet P-40, 10% glycerol, 0.5 µM
phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 3 µg/ml aprotinin) and twice in phosphate-buffered saline, pH 7.4. Proteins bound were separated by SDS-PAGE and immunoblotted using an anti-HA monoclonal antibody (CLONTECH), and visualized by
chemiluminescence (ECL) (Amersham Pharmacia Biotech). For
coimmunoprecipitation, COS-7 cells were cultured to approximately 70%
confluency before they were co-transfected with cDNAs encoding
HA-tagged GCIP and Grap2 or Flag-tagged Grap2. Proteins were
precipitated with specific antibodies and immunoblotted with anti-HA or
anti-cyclin D antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
CAT Assays--
Transfected cells were harvested, and extracts
were prepared by three freeze-thaw cycles and heat inactivation. Cell
lysates were then quantitated for total protein, and an equivalent
amount of cell lysate (normalized for total protein) from each
transfection was assayed for CAT activity as described in
manufacturer's manual (Promega, Madison, WI). Briefly, 50 µg of
total cellular protein (COS-7 transfected cells) were incubated in a
reaction mixture containing 14C-labeled chloramphenicol and
n-butyryl coenzyme A. The reaction products are extracted
with a small volume of xylene. The n-butyryl chloramphenicol
in the xylene phase is mixed with scintillant and counted in a
scintillation counter. Conversion to acetylated forms was also analyzed
by thin-layer chromatography and visualized by autoradiography.
Molecular Cloning of Human GCIP--
To identify proteins that
interact with human Grap2, the COOH-terminal unique
glutamine-/proline-rich domain and the SH3 domain (QC domain) of Grap2
was used as a bait to screen a pretransformed human bone marrow
cDNA library using the yeast two-hybrid system. A number of clones
were identified that contain various lengths of cDNA sequences
derived from a novel gene. One of the clones designated A5 contains a
1.5-kilobase insert and has a full-length open reading frame of 360 amino acids with a predicted molecular mass of 40 kDa (Fig.
1A). We designated the novel
molecule GCIP, Grap2-cyclin-D-interacting
protein, for its association with Grap2 and cyclin D1 in
the cell. As shown in Fig. 1B, GCIP has distinct domain
structures. Secondary structural analysis revealed a putative helix-loop-helix (HLH) motif in the middle region of the protein without the basic DNA-binding domain, suggesting a potential role in
the regulation of transcription factors. A comparison with bHLH
transcription factors and the Id family of proteins reveals the
existence of a conserved second helix domain (Fig. 1C).
However, the first helix domain is very divergent compared with others. An aspartic/glutamic acid-rich domain is found between the HLH domain
and the potential leucine zipper motif. Data base searches found that
the new gene shares 65% homology with mouse Maid, a maternally
transcribed gene that encodes a potential negative regulator of basic
transcription factors in the mouse egg and zygote (17). However, the
human GCIP protein has extra 50 amino acids at its amino terminus (Fig.
1A). To confirm the predicted reading frame of GCIP
cDNA, HA-GCIP plasmids were transfected into COS-7 cells or 293T
cells, proteins were separated by SDS-PAGE and detected by an anti-HA
antibody. As shown in Fig. 2C,
a single band with anticipated molecular mass (approximately 42 kDa) of HA-GCIP was observed on the immunoblot.
Expression of Human GCIP in Normal Human Tissues and in Immune
Tissues--
To examine the expression of the GCIP gene, we performed
Northern blot analysis of mRNAs isolated from different human
tissues. As shown in Fig. 2A, one major transcript of 1.3 kilobases was detected in all the human tissues, including brain,
heart, muscle, colon, thymus, spleen, kidney, liver, small intestine,
placenta, lung, and peripheral blood leukocytes. A higher level of GCIP mRNA expression was observed in heart, muscle, peripheral blood leukocytes, kidney, and brain when compared with other tissues, suggesting a potential negative role of GCIP in cell differentiation and proliferation. Probing mRNA isolated from different immune tissues by RT-PCR demonstrated the expression of GCIP in all immune tissues with relatively low expression in bone marrow (Fig.
2B). An extra band was found in leukocytes, but not in other
immune tissues. Whether the upper band is an alternatively spliced
isoform is under investigation.
Interaction of GCIP with the QC Domain of Grap2 in Yeast
Cells--
To confirm the binding specificity of GCIP with Grap2, we
co-transformed yeast cells with Gal4-AD/GCIP and one of the following expression plasmids: Gal4-DB, Gal4-DB/Grap2QC, and Gal4-DB/Grap2-SH2. The human p53 and large T-antigen serve as a positive control pair in
the study. As shown in Fig.
3A, only yeast cells
co-transformed with GCIP/Grap2 QC plasmids were able to grow on the
selective medium (SD/-Leu/-Trp/-His) other than the positive control.
No growth was observed in cells transformed with GCIP/Grap2 SH2 domain and other plasmids, suggesting that GCIP interacts specifically with
the Grap2 QC domain in yeast cells. To quantitate the interactions between GCIP and Grap2, we measured the GCIP Binds to Adaptor Protein Grap2 in Vitro and in Vivo--
To
verify the binding specificity detected in the yeast two-hybrid assays,
we examined the in vitro binding of GCIP to Grap2. GST
fusion proteins corresponding to different domains of Grap2 (Fig.
4A) were expressed in E. coli and affinity purified by glutathione-Sepharose beads. Lysate
from COS-7 cells transfected with HA-GCIP was incubated with the
immobilized GST-Grap2 fusion proteins. The protein complexes were then
washed extensively, separated by SDS-PAGE, and transferred to a
polyvinylidene difluoride PVDF) membrane. GCIP protein bound to
GST-Grap2 domains was detected with anti-HA monoclonal antibodies. Results from Fig. 4B revealed that HA-GCIP expressed in
COS-7 cells associated with GST-Grap2 full-length protein and the
GST-Grap2 QC domain, thus confirming the results that the QC domain of
Grap2 is responsible for the interaction between Grap2 and GCIP
detected in the yeast two-hybrid system. Neither GST-Grap2-SH2 domain
nor GST alone showed any binding to HA-GCIP, indicating the binding specificity of GCIP to the QC domain of Grap2 fusion protein.
To examine whether GCIP and Grap2 can interact in mammalian cells, we
co-transfected HA-GCIP with Flag-tagged Grap2 in COS-7 cells. Protein
complex was isolated by immunoprecipitation using anti-Flag monoclonal
antibodies (M2). The association of GCIP with Flag-tagged Grap2 was
detected by Western blot using HA-specific monoclonal antibodies. As
shown in Fig. 4C, HA-GCIP coprecipitates with the
full-length Grap2 protein and the QC domain of Grap2, not the Grap2-SH2
domain. Together, these results indicated that GCIP specifically
interacts with the QC domain of Grap2.
GCIP Interacts with Cyclin D1 Protein--
To test whether GCIP is
involved in cell proliferation, we examined the binding of GCIP to
cyclin D by in vitro assays. GST fusion proteins
corresponding to the full-length of GCIP and the carboxyl terminus of
GCIP (Glu209 to Leu360), respectively, were
generated and expressed in E. coli. The GST fusion proteins
were purified by affinity chromatography with glutathion-Sepharose
beads. Cell extracts from 293T cells, COS-7, Jurkat cells, and K562
cells that stimulated with serum were incubated with GST-GCIP fusion
protein. Proteins that bind to GST-GCIP fusion proteins were analyzed
by Western blot using specific anti-cyclin D1 antibody. As shown in
Fig. 5A, the GST-GCIP
full-length fusion protein interacted with cyclin D1 from 293T cell
extract as detected by specific anti-cyclin D1 antibody. No direct
binding of cyclin D1 to the COOH terminus of GCIP or GST beads was
detected. Similar results were obtained with cell extracts from other
cell types (COS-7, Jurkat, and K562 cells).
To further analyze the in vivo binding of GCIP and cyclin D,
we transfected HA-tagged GCIP cDNA into different cells
(Jurkat, K562, COS-7, and 293T). The cells were starved in
serum-free medium initially and subsequently cultured in 10% serum
medium. Cells were lysed 48 h after transfection. Proteins bound
to GCIP were immunoprecipitated using an anti-HA antibody. Protein
complex was separated by SDS-PAGE and subsequently blotted with an
anti-cyclin D1 antibody. As shown in Fig. 5B, cyclin D1 was
coimmunoprecipitated with HA-GCIP in cells transfected with HA-GCIP,
confirming our in vitro observation that GCIP physically
interacts with cyclin D1.
GCIP Regulates Cyclin D-Cdk4 Kinase Activity--
Since GCIP can
interact with cyclin D in cellular extracts, we examined the effects of
GCIP overexpression on the activity of cyclin D-dependent
protein kinase (Cdk4). Cyclin D1-Cdk4 complex was immunopurified from
COS-7 cells by either anti-cyclin D1 antibodies or anti-Cdk4
antibodies. The activity of the cyclin D-Cdk4 complex was assayed by
its ability to phosphorylate the carboxyl-terminal domain of Rb
expressed as a GST fusion protein. As shown in Fig. 6, overexpression of GCIP in COS-7 cells
reduced the phosphorylation of GST-Rb protein by approximately 50%
when the cyclin D-Cdk4 complex was precipitated with anti-Cdk4
antibodies. On the other hand, GCIP has less inhibitory effect on the
phosphorylation of GST-Rb (30%) by the cyclin-D-Cdk4 complex purified
by anti-cyclin D1 antibodies. Similar inhibitory effect (~30-40%)
was observed by adding purified GST-GCIP protein into the
phosphorylation reaction of GST-Rb (data not shown). These data suggest
that interaction of GCIP with cyclin D1 reduced the kinase activity of
the cyclin D-Cdk4 complex either by disrupting the complex formation or
by changing the conformation of the complex.
GCIP Regulates E2F-mediated Transcriptional Activity--
Since
phosphorylation of Rb by cyclin D-dependent protein kinases
leads to the activation of E2F transcriptional activation by releasing
E2F from Rb (18, 19), we examined whether binding of GCIP to cyclin D
has any effect on the activation of E2F-mediated transcription. First,
a chimeric E2F protein with the carboxyl-terminal transcription
activation domain of E2F1 was fused to a GAL4 DNA-binding domain for
its ability to respond to the overexpression of GCIP in
transient-transfection assay as described previously (20-22). As shown
in Fig. 7A, the GAL4-E2F1
expression vector and the control vector GAL4VP16 could induce
transcription activation from a pG5E1BCAT reporter. Co-transfection of
GCIP greatly inhibited the transcriptional activity of the GAL4-E2F1
protein, but has little effect on the transcription induced by the
GAL4-VP16. Similar results were obtained with the CAT assay on the thin
layer plates where co-transfection of GCIP inhibited the CAT activity
(Fig. 7B). These results suggested that GCIP directly or
indirectly inhibited the transcriptional activation mediated by E2F1
protein.
We have cloned a novel human protein from bone marrow library,
GCIP, that bound to the leukocyte-specific adaptor protein Grap2 and
the key cell cycle protein, cyclin D. Expression of GCIP mRNA was
found in most of the human tissues, especially abundant in the heart,
muscle, peripheral blood leukocytes, brain, and kidney. From the
two-hybrid system and in vitro binding assays, we found that
GCIP interacted with the QC domain of Grap2. We also showed that GCIP
protein could interact with cyclin D both in our in vitro
assays and in GCIP-transfected cells in which GCIP can be
coimmunoprecipitated with cyclin D. Furthermore, the presence of GCIP
in cyclin D-Cdk4 complex decreased the cyclin D-dependent
kinase activity using GST-Rb as a substrate. These results suggest that
association of GCIP with cyclin D may change the conformation of cyclin
D-Cdk4 complexes or prevent cyclin D to form stable complex with Cdks,
which is essential for the phosphorylation of Rb by fully active kinase
complex. Overexpression of GCIP in COS-7 cells indirectly or directly
inhibited the E2F1 mediated transcriptional activity. By interacting
with cyclin D, GCIP may regulate the phosphorylation status of Rb
protein, leading to the inhibitory effects of E2F transcriptional
activity. Since GCIP contains a putative HLH structure without the
basic DNA-binding domains, it may function as a dominant negative
regulator for transcription factors like the Id family of proteins
(23-26). Therefore, GCIP may directly interact with transcription
factor E2F1, blocking the transcriptional activity of E2F1 in our
reporter assays. We are currently examining the molecular basis
of this inhibitory effect of GCIP on transcription factors.
The characteristic of HLH without the basic amino acid region
identified in GCIP is similar to that of the Id proteins, a family of
negative regulators of bHLH transcription factors (23, 24, 27-30).
However, the amino acid sequence of GCIP shares little identity with
the Id proteins (Id1, Id2, Id3, and Id4). Therefore, GCIP may represent
a new class of dominant negative HLH proteins, similar to the mouse
maternally transcribed gene, Maid (17). Following the putative HLH
domain is a region enriched with aspartic and glutamic acids in GCIP.
Domains with high acidic amino acid content are considered to be
involved in protein-protein interactions. Immediately downstream of the
negatively charged domain of GCIP is a potential leucine zipper
(leucine-rich) domain, suggesting that these regions may be involved in
interactions with other proteins. Due to the structural features of
GCIP, it will be of great interest to examine whether GCIP could
interact with HLH domain-containing transcription factors and act as a
negative regulator in cell differentiation and proliferation.
Grap2 is a novel adaptor protein identified by its interaction with
Gab-1 docking protein (14). Similar to Grb2, Grap2 contains two SH3
domains and one SH2 domain. However, Grap2 also contains a unique
120-amino acid proline-/glutamine-rich domain between the SH2 domain
and the COOH-terminal SH3 domain. Unlike Grb2, the expression of Grap2
is exclusively limited to immune tissues, e.g. high level of
expression in the thymus, spleen, bone marrow, peripheral blood
leukocyte, and lymph nodes. There is no or little expression in other
tissues tested. In immune cells, Grap2 is found primarily in T
lymphocytes,
monocytes/macrophages.2
During the activation of T lymphocytes, Grap2 plays an important role
in transducing signals from cell surface membrane to the nucleus by
interacting with different signaling molecules and forming signal
transduction complexes. The identification of a novel protein GCIP that
interacts with Grap2 and cyclin D will further confirm our hypothesis
that Grap2 is a central linker protein in immune cell signaling and
proliferation. Signaling pathways linked to Grap2 complex could
directly or indirectly affect E2F1 transcriptional activity, a possible
mechanism for the regulation of cell cycle and cell proliferation.
Other adaptor proteins that contain similar domain structures may also
interact with GCIP in different tissues or cells. With distinct domain structure found in GCIP, it will be interesting to examine the kinds of
molecules that interact with GCIP during cell differentiation and proliferation.
Regulation of mammalian cell proliferation by extracellular signals is
governed through receptor-mediated signaling networks that ultimately
converge on the cell cycle machinery driven by cyclin-dependent kinases and cyclin-dependent
kinases inhibitors (6). The transition from G1 to S phase
is controlled by a series of sequential regulatory events.
We demonstrated that GCIP interacts with cyclin D and this interaction
could exert negative effect on the cyclin D-dependent Cdk4
kinase activity. In mammalian cells, expression of D-type cyclins is an
early event stimulated by growth factors, cytokins, and other mitogens.
D-type cyclins bind and activate cyclin-dependent kinases
Cdk4 and Cdk6. Cyclin D-Cdk complexes phosphorylate the retinoblastoma
family of proteins, Rb, that reversibly interacts with members of the
E2F family of transcription factors and inhibits the transcriptional
activity of E2F (18, 19, 31-33). Phosphorylation of Rb during
G1 phase inactivates the ability of Rb to control cell
cycle progression, leading to the accumulation of active E2F and
possibly other transcription factors required to drive the cell into S
phase (34, 35). In this report, we have shown that overexpression of
GCIP in cells inhibited the E2F1-mediated transcriptional activity.
Although GCIP mRNA is found in most of the human tissues examined,
the expression level of GCIP is substantially higher in the heart,
muscle, peripheral blood leukocytes, lung, and brain where cell
differentiation and proliferation is limited in normal tissues.
Therefore, it is tempting to hypothesize that GCIP, together with other
transcriptional inhibitors, is the underlining mechanism that regulates
cell proliferation and differentiation. Studies on how the expression
of GCIP is regulated by cell cycle signals and during cell
proliferation will shed new light on the molecular mechanism of cell
differentiation and proliferation.
We are grateful to Dr. David Johnson, Dr.
Meng-Hong Lee (University of Texas, M.D. Anderson Cancer Center), and
Dr. Xin-Hua Feng (Baylor College of Medicine) for valuable constructs.
*
This work was supported in part by Scientist Development
Grant 0030160N from the American Heart Association National (to M. L.) and a National Science Foundation grant (to M. Q.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Contributed equally to the results of this work.
§§
To whom correspondence should be addressed: Center for Cancer
Biology and Nutrition, Institute of Biosciences and Technology, Texas
A&M University System Health Science Center, 2121 W. Holcombe Blvd.,
Houston, TX 77030. Tel.: 713-677-7505; Fax: 713-677-7512; E-mail:
mliu@ibt.tamu.edu.
Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M002598200
2
C. Xia and M. Liu, unpublished data.
The abbreviations used are:
Rb, retinoblastoma
protein;
SH, Src homology domain;
RT-PCR, reverse
transcriptase-polymerase chain reaction;
HA, hemagglutinin;
GST, glutathione S-transferase;
CAT, chloramphenicol
acetyltransferase;
HLH, helix-loop-helix;
Cdk4, cyclin
D-dependent protein kinase;
PAGE, polyacrylamide gel
electrophoresis.
GCIP, a Novel Human Grap2 and Cyclin D Interacting Protein,
Regulates E2F-mediated Transcriptional Activity*
§,
§¶,
,
,
,
, and
§§
Department of Medical Biochemistry and
Genetics, Center for Cancer Biology and Nutrition, Institute of
Biosciences and Technology, Texas A&M University System Health Science
Center, Houston, Texas 77030, the ¶ Ocean University of Qingdao,
Qingdao, 266003 People's Republic of China, the
Department of
Anatomical Sciences and Neurobiology, School of Medicine, University of
Louisville, Louisville, Kentucky 40292, and ** Clontech Laboratories,
Inc., Palo Alto, California 94303
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase activity. Library plasmid DNA was recovered by transformation into Escherichia coli KC8
cells and sequenced on both strands.
-32P]dCTP (3000 Ci/mmol; ICN
Pharmaceuticals, Costa Mesa, CA) by random priming, using the Prime-It
random primer labeling kit (Stratagene, La Jolla, CA) according to the
manufacturer's directions. The hybridizing and washing conditions were
as described in the manual provided with ExpressHyb hybridization
solution (CLONTECH) with the modification that
hybridization was carried out for 4 h at 68 °C in a
hybridization oven. After hybridization, the blots were washed first in
2 × sodium citrate buffer and 0.5% SDS buffer for 30 min at room
temperature, then followed by three washes with 0.1 × sodium
citrate buffer and 0.1% SDS buffer solutions at 50-60 °C. The
membrane was exposed to x-ray film (Kodak BioMax MR) for 24 h at
80 °C.
-glycerophosphate, 1% Triton X-100, 0.5% Nonidet P-40, 10%
glycerol, 0.5 µM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 3 µg/ml aprotinin). Kinase assays for cyclin D-Cdk4 were
performed using GST-Rb as a substrate as described previously (15).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (46K):
[in a new window]
Fig. 1.
Deduced amino acid sequence and domain
organization of human GCIP. A, amino acid sequence of
human GCIP. A total of 360 amino acids are deduced from the open
reading frame. B, the potential domain structure of human
GCIP. A tentative helix-loop-helix domain is followed by a Asp/Glu-rich
acidic domain. A potential leucine zipper domain is also found with one
amino acid substitution (Leu-Cys) in GCIP. C, comparison of
the potential motif of HLH of GCIP with other bHLH and dnHLH proteins:
c-Myc (36), sleraxis (37), myogenin (38), eHAND (39), MyoR (40),
neurogenin (41), Id1 and Id3 (27). The consensus sequence of the bHLH
region was derived from Murre et al. (42).
in the
consensus sequence indicates hydrophobic amino acids.

View larger version (37K):
[in a new window]
Fig. 2.
Expression of human GCIP.
A, Northern blot analysis of GCIP in different
human adult tissues. mRNA derived from different human adult
tissues were obtained from CLONTECH and hybridized
with a radiolabeled GCIP probe. Twelve different human tissues are:
1, brain; 2, heart; 3, muscle;
4, colon; 5, thymus; 6, spleen;
7, kidney; 8, liver; 9, small
intestine; 10, placenta; 11, lung; and
12, peripheral blood leukocytes. The size of the GCIP
cDNA was estimated to be approximately 1.4 kilobases with minor
bands at 4.0 kilobase. B, PCR analysis of the expression of
GCIP mRNA in immune tissues. cDNA from different immune tissues
were obtained from CLONTECH. Specific primers of
human GCIP (5'-CTACAACAGTGTCTGGGTTGCGTGCC;
3'-GTATCAGAGCCTGTCCATGTCGATGAG) were used to detect the expression of
the gene. Relative lower expression of GCIP was found in bone marrow
compared with other immune tissues. Two different sizes of products are
present in leukocytes, reflecting possible alternative splicing
products. No cDNA was added in the control panel. G3PDH,
glyceraldehyde-3-phosphate dehydrogenase. C, expression of
HA-tagged GCIP protein in COS-7 cells. COS-7 cells were transfected
with HA-tagged GCIP cDNA and the control plasmid pCMV-HA. A 42-kDa
protein was detected in cells transfected with HA-GCIP.
-galactosidase activity of
the lacZ reporter gene and compared that with the
interaction between p53 and large T-antigens. As shown in Fig.
3B, co-transformation of GCIP with the QC domain of Grap2 in
yeast cells strongly activated the expression of the lacZ
reporter gene. These results clearly demonstrated that in
vivo binding of GCIP to Grap2 is highly specific in yeast
cells.

View larger version (35K):
[in a new window]
Fig. 3.
Interaction of GCIP with the QC domain of
Grap2 in yeast two-hybrid system. A, yeast cells
co-transformed with Gal4-AD/GCIP and Gal4-BD/Grap2-QC domain can grow
on selective plate (SD/-Leu/-Trp/-His), indicating in vivo
interaction of GCIP and Grap2-QC domain in yeast cells. p53 and large
T-antigen are known proteins that interact each other in the cell and
used as a positive control. B, activation of lacZ
reporter gene activity in cells co-transformed with GCIP and Grap2-QC
domain. Like p53 and large T-antigen, co-transformation of GCIP with
Grap2-QC domain greatly increased lacZ gene expression
(hence the
-gal activity). 1, Grap2 QC alone;
2, p53 and large T-antigen; 3, GCIP and Grap2-QC
domain; 4, GCIP and Grap2-SH2 domain; 5, GCIP
alone.

View larger version (22K):
[in a new window]
Fig. 4.
Binding of GCIP to Grap2-QC domain in
vitro and in vivo. A, schematic
diagram of GST-Grap2 fusion protein. GST fusion proteins corresponding
to the Grap2 full-length (FL), the SH2 domain, and the QC
domain were constructed, expressed in E. coli, and purified
by affinity purification. B, HA-tagged GCIP binds to
full-length GST-Grap2 full-length protein and GST-Grap2-QC fusion
protein, but not the SH2 domain. C, GCIP co-precipitated
with Grap2 and Grap2-QC domain in mammalian cells. cDNAs encoding
HA-tagged GCIP and Flag-tagged Grap2 or Grap2-QC domain were
co-transfected into COS-7 cells. Proteins were precipitated using
anti-Flag monoclonal antibody, M2. Proteins bound to Flag-Grap2 were
detected by Western blot analysis using specific anti-HA monoclonal
antibody.

View larger version (36K):
[in a new window]
Fig. 5.
Association of GCIP with cyclin D1.
A, GST-GCIP fusion protein binds to cyclin D1. Two
GST-fusion proteins corresponding to the full-length and the COOH
terminus of GCIP were produced in E. coli and purified by
glutathion-agarose beads. COS-7 cell extracts are incubated with the
GST fusion proteins. Proteins bound to the GST fusion proteins were
analyzed by Western blot. Cyclin D1 was found to associate with the
full-length GST-GCIP protein, but not the COOH terminus. The amount of
cyclin D used in the cell extract is similar as seen in the lower
panel. B, coimmunoprecipitation of HA-GCIP with cyclin
D1 in different cells. HA-tagged GCIP cDNA was transfected into
different cells and precipitated by monoclonal antibody against HA or
cyclin D1. Cyclin D1 was detected in the HA-GCIP precipitate using
specific anti-cyclin D1 antibody. As a positive control (last
lane), anti-cyclin D1 antibody was used to precipitate the protein
in COS-7 lysate.

View larger version (29K):
[in a new window]
Fig. 6.
Phosphorylation of Rb by Cdk4 is inhibited by
GCIP. Overexpression of GCIP in COS-7 cells reduced the activity
of cyclin D-dependent protein kinase (Cdk4). The protein
kinase complex was immunoprecipitated by specific anti-Cdk4 or
anti-cyclin D antibodies. GST-Rb fusion protein corresponding to the
COOH terminus of Rb protein is kindly provided by Dr. Meng-Hong Lee at
the University of Texas, M.D. Anderson Cancer Center. The fusion
protein was expressed in E. coli and purified by
gluthione-agarose column. Purified GST-Rb fusion protein is used as the
phosphorylation substrate. The intensity of the phosphorylated GST-Rb
fusion protein was digitized. Phosphorylation of GST-Rb is expressed as
100% in the absence of GCIP. Percentage of inhibition by human GCIP
was calculated in the presence of the protein.

View larger version (26K):
[in a new window]
Fig. 7.
Repression of E2F1-mediated transcriptional
activity by human GCIP. A, a pG5E1BCAT reporter was
induced by transfecting the indicated GAL-4 fusion proteins.
Co-transfection of 2 µg of cDNAs encoding GCIP or Rb dramatically
represses Gal4-E2F1 protein induced CAT activity. Much less effect of
GCIP on the inhibition of GAL4-VP16 was observed. COS-7 cells were
transiently transfected with pG5E1BCAT reporter and expression vectors
indicated beneath each column. B, repression of
E2F1-activated CAT activity by GCIP in thin layer chromatography assay.
Co-transfection of GCIP inhibited E2F1 mediated CAT activity. Cell
extracts were incubated with [14C]chloramphenicol and
n-butyryl coenzyme A. The reaction mixture were extracted
and run on thin layer chromatography. The CAT activity was visualized
by exposing to x-ray film for 2-7 days.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

Current address: Calydon, Inc., Sunnyvale, CA 94089.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Sherr, C. J.
(1993)
Cell
73,
1059-1065
2.
Meyerson, M.,
and Harlow, E.
(1994)
Mol. Cell. Biol.
14,
2077-2086
3.
Weinberg, R. A.
(1995)
Cell
81,
323-330
4.
Nevins, J. R.
(1998)
Cell Growth Differ
9,
585-593
5.
Chellappan, S. P.,
Giordano, A.,
and Fisher, P. B.
(1998)
Curr. Top. Microbiol. Immunol.
227,
57-103
6.
Sherr, C. J.,
and Roberts, J. M.
(1999)
Genes Dev.
13,
1501-1512
7.
Dyson, N.
(1998)
Genes Dev.
12,
2245-2262
8.
Johnson, D. G.,
and Walker, C. L.
(1999)
Annu. Rev. Pharmacol. Toxicol.
39,
295-312
9.
Weng, G.,
Bhalla, U. S.,
and Iyengar, R.
(1999)
Science
284,
92-96
10.
Bhalla, U. S.,
and Iyengar, R.
(1999)
Science
283,
381-387
11.
Choi, K.-Y.,
Satterberg, B.,
Lyons, D. M.,
and Elion, E. A.
(1994)
Cell
78,
499-512
12.
Whitmarsh, A. J.,
Cavanagh, J.,
Tournier, C.,
Yasuda, J.,
and Davis, R. J.
(1998)
Science
281,
1671-1674
13.
Zhang, W.,
Sloan-Lancaster, J.,
Kitchen, J.,
Trible, R. P.,
and Samelson, L. E.
(1998)
Cell
92,
83-92
14.
Qiu, M.,
Hua, S.,
Agrawal, M.,
Li, G.,
Cai, J.,
Chan, E.,
Zhou, H.,
Luo, Y.,
and Liu, M.
(1998)
Biochem. Biophys. Res. Commun.
253,
443-447
15.
Matsushime, H.,
Quelle, D. E.,
Shurtleff, S. A.,
Shibuya, M.,
Sherr, C. J.,
and Kato, J. Y.
(1994)
Mol. Cell. Biol.
14,
2066-2076
16.
Johnson, D. G.,
Ohtani, K.,
and Nevins, J. R.
(1994)
Genes Dev.
8,
1514-1525
17.
Hwang, S.-Y.,
Oh, B.,
Fuchtbauer, A.,
Fuchtbauer, E.-M.,
Johnson, K. R.,
Solter, D.,
and Knowles, B. B.
(1997)
Dev. Dyn.
209,
217-226
18.
Chellappan, S. P.,
Hiebert, S.,
Mudryj, M.,
Horowitz, J. M.,
and Nevins, J. R.
(1991)
Cell
65,
1053-1061
19.
Hiebert, S. W.,
Chellappan, S. P.,
Horowitz, J. M.,
and Nevins, J. R.
(1992)
Genes Dev.
6,
177-185
20.
Johnson, D. G.,
Schwarz, J. K.,
Cress, W. D.,
and Nevins, J. R.
(1993)
Nature
365,
349-352
21.
Cress, W. D.,
and Nevins, J. R.
(1994)
J. Virol.
68,
4213-4219
22.
Wang, S.,
Nath, N.,
Fusaro, G.,
and Chellappan, S.
(1999)
Mol. Cell. Biol.
19,
7447-7460
23.
Benezra, R.,
Davis, R.,
Lockshon, D.,
Turner, D.,
and Weintraub, H.
(1990)
Cell
61,
49-59
24.
Christy, B.,
Sanders, L.,
Lau, L.,
Copeland, N.,
Jenkins, N.,
and Nathans, D.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1815-1819
25.
Deed, R. W.,
Bianchi, S. M.,
Atherton, G. T.,
Johnston, D.,
Santibanez-Koref, M.,
Murphy, J. J.,
and Norton, J. D.
(1992)
Oncogene
8,
599-607
26.
Riechmann, V.,
van Cruchten, I.,
and Sablitzky, F.
(1994)
Nucleic Acids Res.
22,
749-755
27.
Norton, J. D.,
Deed, R. W.,
Craggs, G.,
and Sablitzky, F.
(1998)
Trends Cell Biol
8,
58-65
28.
Sun, X. H.,
Copeland, N. G.,
Jenkins, N. A.,
and Baltimore, D.
(1991)
Mol. Cell. Biol.
11,
5603-5611
29.
Lyden, D.,
Young, A. Z.,
Zagzag, D.,
Yan, W.,
Gerald, W.,
O'Reilly, R.,
Bader, B. L.,
Hynes, R. O.,
Zhuang, Y.,
Manova, K.,
and Benezra, R.
(1999)
Nature
401,
670-677
30.
Jen, Y.,
Weintraub, H.,
and Benezra, R.
(1992)
Genes Dev.
6,
1466-1497
31.
Dynlacht, B. D.
(1997)
Nature
389,
149-152
32.
Ross, J. F.,
Liu, X.,
and Dynlacht, B. D.
(1999)
Mol Cell
3,
195-205
33.
Harbour, J. W.,
Luo, R. X.,
Dei Santi, A.,
Postigo, A. A.,
and Dean, D. C.
(1999)
Cell
98,
859-869
34.
Weintraub, S. J.,
Chow, K. N.,
Luo, R. X.,
Zhang, S. H.,
He, S.,
and Dean, D. C.
(1995)
Nature
375,
812-815
35.
Qin, X. Q.,
Livingston, D. M.,
Ewen, M.,
Sellers, W. R.,
Arany, Z.,
and Kaelin, W. G., Jr.
(1995)
Mol. Cell. Biol.
15,
742-755
36.
De Pinho, R.,
Mistock, L.,
Hatton, K.,
Ferrier, P.,
Zimmerman, K.,
Legouy, E.,
Tesfaye, A.,
Collum, R.,
Yanocopoulos, G.,
and Niesen, P.
(1987)
J. Cell Biol.
33,
257-266
37.
Cserjesi, P.,
Brown, D.,
Ligon, K. L.,
Lyons, G. E.,
Copeland, N. G.,
Gilbert, D. J.,
Jenkins, N. A.,
and Olson, E. N.
(1995)
Development
121,
1099-1110
38.
Wright, W. E.,
Sassoon, D. A.,
and Lin, V. K.
(1989)
Cell
56,
607-617
39.
Cserjesi, P.,
Brown, D.,
Lyons, G. E.,
and Olson, E. N.
(1995)
Dev. Biol.
170,
664-678
40.
Lu, J.,
Webb, R.,
Richardson, J. A.,
and Olson, E. N.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
552-557
41.
Ma, Q.,
Kintner, C.,
and Anderson, D. J.
(1996)
Cell
87,
43-52
42.
Murre, C.,
McCaw, P. S.,
and Baltimore, D.
(1989)
Cell
56,
777-783
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
P.-C. Chu, Y.-C. Yang, Y.-T. Lu, H.-T. Chen, L.-C. Yu, and M.-S. Chang Silencing of p29 Affects DNA Damage Responses with UV Irradiation. Cancer Res., September 1, 2006; 66(17): 8484 - 8491. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Behbod, W. Xian, C. A. Shaw, S. G. Hilsenbeck, A. Tsimelzon, and J. M. Rosen Transcriptional Profiling of Mammary Gland Side Population Cells Stem Cells, April 1, 2006; 24(4): 1065 - 1074. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Bonome, J.-Y. Lee, D.-C. Park, M. Radonovich, C. Pise-Masison, J. Brady, G. J. Gardner, K. Hao, W. H. Wong, J. C. Barrett, et al. Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary Cancer Res., November 15, 2005; 65(22): 10602 - 10612. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Guo, L. J. Stafford, B. Bryan, C. Xia, W. Ma, X. Wu, D. Liu, Z. Songyang, and M. Liu A Rac/Cdc42-specific Exchange Factor, GEFT, Induces Cell Proliferation, Transformation, and Migration J. Biol. Chem., April 4, 2003; 278(15): 13207 - 13215. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bourgin, R. P. Bourette, S. Arnaud, Y. Liu, L. R. Rohrschneider, and G. Mouchiroud Induced Expression and Association of the Mona/Gads Adapter and Gab3 Scaffolding Protein during Monocyte/Macrophage Differentiation Mol. Cell. Biol., June 1, 2002; 22(11): 3744 - 3756. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |